Get the Stockscreener App
762.18
1.23%
-9.53
After Hours:
763.00
0.82
+0.11%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $762.18, with a volume of 3.01M.
It is down -1.23% in the last 24 hours and down -0.07% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$771.71
Open:
$768.17
24h Volume:
3.01M
Relative Volume:
0.78
Market Cap:
$722.35B
Revenue:
$49.00B
Net Income/Loss:
$11.11B
P/E Ratio:
62.02
EPS:
12.29
Net Cash Flow:
$-1.27B
1W Performance:
-4.65%
1M Performance:
-0.07%
6M Performance:
+2.67%
1Y Performance:
-11.11%
1-Day Range:
$760.50
$772.00
1-Week Range:
$760.02
$805.42
52-Week Range:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
762.18 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
164.36 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
184.85 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.14 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
64.92 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly’s Strategic Advantage in GLP-1RAs and Alzheimer’s Markets Fuels Buy Rating - TipRanks
Eli Lilly: Competition Melts Away (NYSE:LLY) - Seeking Alpha
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool
Bernstein Remains Bullish on Eli Lilly and Company (LLY) With an $1,100 PT - Insider Monkey
Eli Lilly acquires Verve Therapeutics in $1.3 billion deal, validating gene editing for heart disease - drugdiscoverytrends.com
Why Eli Lilly (LLY) is Emerging as a Dividend Growth Leader in Pharma for 2025 - Insider Monkey
J.P. Morgan Sees Strong Q2 for Eli Lilly, Maintains Overweight Rating - Insider Monkey
Eli Lilly and Company - Lifespan Research Institute
Is Eli Lilly Stock A Buy On A Fresh Bout Of Alzheimer's News? - Investor's Business Daily
Eli Lilly’s Innovative Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
Eli Lilly’s New Study on LY4050784: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s LUCENT 3 Study: A Promising Step for Ulcerative Colitis Treatment - TipRanks
Eli Lilly’s KRAS Inhibitor Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Eli Lilly’s Lepodisiran Study: A Step Forward in Liver Function Treatment - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer in Obesity Treatment - TipRanks
Eli Lilly’s Promising Phase 1 Study on LY4101174: A Potential Game-Changer in Cancer Treatment - TipRanks
Eli Lilly’s New Cancer Study: A Potential Game-Changer? - TipRanks
Eli Lilly & Co: Analyst Bullish on Diabetes Segment and Oncology Franchise Amid Competitive Pressures. - AInvest
Eli Lilly & Co: Promising Growth Prospects and Strategic Positioning Amid Competitive Pressures - TipRanks
Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs? - The Motley Fool
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers By Investing.com - Investing.com India
Abbott, Eli Lilly Lead Thursday’s Market Cap Stock Movers - Investing.com
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today? - Yahoo Finance
Senators reveal how much Lilly, Pfizer paid telehealth companies - statnews.com
LLY Stock Quote Price and Forecast - CNN
Eli Lilly Bets Big On Obesity And Diabetes Drugs - Finimize
Jim Cramer on Eli Lilly: “How Can You Leave This One Right Here?” - MSN
ELI LILLY AND COMPANY (LLY) - MSN
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound - CNBC
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Benzinga
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Eli Lilly & Co (LLY) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Stoke Therapeutics (STOK) - The Globe and Mail
Health Canada Expands Eli Lilly's Omvoh Indication to Crohn's, Approves Citrate-Free Formula - MarketScreener
Verve Offers $416K Award To GC Amid Lilly Acquisition - Law360
Eli Lilly’s Weight-Loss Drug Faces New Competition from China - TipRanks
Eli Lilly Foundation provides $5.5 million grant for STEM education initiative at IPS - Fox 59
The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises - Yahoo Finance
Eli Lilly: Still Too Pricey To Buy (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Secures FDA Label Update for Alzheimer’s Disease Treatment - Insider Monkey
Eli Lilly (LLY) Gains Health Canada Approval for Omvoh in Crohn's Disease Treatment - GuruFocus
Eli Lilly’s Obesity Pill For The Masses Could Flip The $150 Billion Market on Its Head! - Smartkarma
Top Research Reports for Eli Lilly, Netflix & GE Aerospace - Yahoo Finance
Eli Lilly (LLY) Expects Results from Weight-Loss Pill Trial by Sept. 30 - TipRanks
Eli Lilly’s Weight Management Study: A Potential Game-Changer? - TipRanks
Eli Lilly’s New Study on SGLT2 Inhibitors: A Potential Game-Changer for CKD Anemia Management - TipRanks
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (July 2025) - 24/7 Wall St.
Eli Lilly and Company (LLY) Stock Analysis: Exploring a Potential 20% Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into Indias Weigh-Loss Drug Sector - NDTV Profit
Eli Lilly and Company (LLY): I Would “Love” If Trump Praised The Company, Says Jim Cramer - Insider Monkey
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth - Yahoo Finance
Eli Lilly Surges Ahead: JPMorgan Sees $1,100 Price Target on Obesity Drug Boom - Yahoo
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):